Safety of catheter ablation of atrial fibrillation in cancer survivors

Purpose In patients with cancer, the safety of catheter ablation for non-valvular atrial fibrillation (AF) has not been evaluated, yet. The aim of this study was to assess the safety of AF ablation in cancer survivors. Methods Consecutively recruited patients undergoing catheter ablation of non-valv...

Full description

Saved in:
Bibliographic Details
Published in:Journal of interventional cardiac electrophysiology 2021-04, Vol.60 (3), p.419-426
Main Authors: Giustozzi, Michela, Ali, Hussam, Reboldi, Gianpaolo, Balla, Cristina, Foresti, Sara, de Ambroggi, Guido, Lupo, Pier Paolo, Agnelli, Giancarlo, Cappato, Riccardo
Format: Article
Language:English
Subjects:
Ablation
Anticoagulants
Bleeding
Breast
Cancer
Cardiac arrhythmia
Cardiology
Catheters
Evaluation
Fibrillation
Medical instruments
Medicine
Medicine & Public Health
Multimedia Report
Radiofrequency ablation
Safety
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose In patients with cancer, the safety of catheter ablation for non-valvular atrial fibrillation (AF) has not been evaluated, yet. The aim of this study was to assess the safety of AF ablation in cancer survivors. Methods Consecutively recruited patients undergoing catheter ablation of non-valvular AF at our center between March 2015 and March 2017 were evaluated. The primary outcome of the study was clinically relevant bleedings occurred within 30 ± 5 days after the procedure. Patients with cancer were propensity matched to patients without cancer in a 1:3 and 1:6 ratio after stratification by baseline clinical features. Results Overall, 184 patients were included in the study. Of them, 21 (11%) were cancer survivors. Cancer site was more frequently gastrointestinal (36%), breast (23%), and genitourinary (18%). At 30 ± 5 days, clinically relevant bleedings occurred in 14 patients. Crude odds ratio (OR) for clinically relevant bleedings was 3.60 (95% CI 1.02–12.7) higher in cancer than in non-cancer patients. This trend remained after propensity score–matched population (OR 3.48, 95% CI 0.76–15.90 for matched 1:3, OR 4.95, 95% CI 1.2–20.2 for matched 1:6). Type of anticoagulation was not associated with bleedings. Conclusions Preliminary results suggest that clinically relevant bleeding after catheter ablation for AF is more frequent in cancer survivors than in patients without cancer. Further studies are required to confirm the present data.
ISSN:1383-875X
1572-8595
DOI:10.1007/s10840-020-00745-7